Inactive

The purpose of this amendment is to extend the due date of the quote submission deadline to 11:59 pm EST, September 4, 2024. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~... The purpose of this amendment is to extend the due date of the quote submission deadline to 11:59 pm EST, September 4, 2024. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number for this requirement is 75D301-24-Q-78076 and is hereby issued as a Request for Quote (RFQ). The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular FAC 2024-05 dated May 22, 2024. The associated North American Industrial Classification System (NAICS) code for this procurement 334513 —Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variable. This is a RFQ for the procurement of Bio-Rad OPUS Dx instruments for detection of influenza and SARS-CoV-2 from clinical specimens. The Government intends to award a Firm-Fixed Price (FFP) contract as a result of this solicitation that will include the terms and conditions that are set forth herein. The provision at 52.212-1, Instructions to Offerors-Commercial, applies to this acquisition along with the addenda to the provision included in the solicitation document. FAR 52.212-2, Evaluation-Commercial Items, is included, and the specific evaluation criteria are included in paragraph (a) of that provision. Offerors shall include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer or indicate if it is available online at SAM.gov. FAR 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition; there are no addenda to the clause. FAR 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition and the additional FAR clauses cited in the clause that are applicable have been noted. There are no additional contract requirement(s) or terms and conditions determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices. No telephonic quotes will be processed. All responses must be received no later than the date stated above. Inquiries shall reference the solicitation number 75D301-24-Q-78076, on the subject line and be sent to the Contract Specialist, Dawnnia Daley by email at xwf5@cdc.gov

Inactive

The Center for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases Influenza Division (NCIRD/ID), intends to award a sole source purchase order in accordanc... The Center for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases Influenza Division (NCIRD/ID), intends to award a sole source purchase order in accordance with FAR 13.106-1(b)(1), soliciting from a single source, to Bio-Rad Laboratories Inc., 4000 Alfred Nobel Dr., Hecules, California 94547, for Bio-Rad OPUS DX instruments to detect influenza and SARS-CoV-2 from clinical specimens. These instruments are proprietary to Bio-Rad and are FDA-approved in vitro diagnostic (IVD) and reverese-transcriptase real-time polymerase chain reaction (rRT-PCR) instruments. The NAICS code for this procurement is 334513, Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables. The purpose of this acquisition is to purchase Bio-Rad OPUS Dx instruments to evaluate the performance of our FDA-cleared and FDA-approved in vitro diagnostic assays for influenza and SARS-CoV-2 on this instrument. The Bio-Rad OPUS Dx can multiplex up to 5 targets per well. Moreover, it uses a distinct method for collecting the data in each well that is unique to BioRad instruments. BioRad is the only company that produces the OPUS Dx 96-well rRT-PCR instrument. Consequently, the CDC,NCIRS/ID is considering Bio-Rad Laboratories Inc. for a sole-source award to fulfill this requirement. As a result of this notice, no competitive solicitation will be posted on SAM.gov. The government will issue only one solicitation to Bio-Rad Laboratories Inc. However, firms that believe they can meet this requirement are encouraged to identify themselves and give written notice by providing a capability statement to the contract specialist, Dawnnia Daley, at xwf5@cdc.gov by August 7, 2024, at 5:00 p.m. EDT. The contract specialist will not respond to verbal requests. All requests must be in writing. A determination by the government not to take this proposed action will be based on responses to this notice and is solely within the discretion of the contracting officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall reference the solicitation number, 75D301-24-Q-78076, on the subject line and be sent to Dawnnia Daley by email at xwf5@cdc.gov.